Prime Minister Mark Carney on April 21-22 unveiled a 24-member Advisory Committee on Canada‑U.S. Economic Relations to advise Ottawa ahead of the Canada‑United States‑Mexico Agreement (USMCA/CUSMA) review due on July 1, 2026. The panel, to be chaired by Trade Minister Dominic LeBlanc, meets first on April 27 and combines business chiefs, union leaders and former politicians. Notable members include former Conservative leader Erin O’Toole, ex‑Quebec premier Jean Charest, former high commissioner Ralph Goodale, Unifor’s Lana Payne and CEOs from BMO, CN, TC Energy, Teck and Nutrien. Carney retained only a handful of advisers from the previous council. Canada’s chief negotiator Janice Charette warned businesses on April 22 to expect “some turbulence” in talks and urged firms to lobby U.S. partners, saying negotiations likely will not be wrapped up by the July 1 checkpoint. The advisory body is aimed at shaping strategy to defend tariff-free access for much Canadian trade while confronting U.S. tariffs on steel, aluminum and autos and preparing for possible bilateral side‑deals alongside trilateral talks.

SpaceX announced a partnership with AI coding startup Cursor that gives the rocket maker the right to acquire the company for $60 billion later this year or, if it declines to buy, to pay $10 billion for the collaborative work. The deal pairs Cursor’s developer-focused code-generation products with SpaceX’s Colossus training cluster — described by the company as the equivalent of roughly a million Nvidia H100 GPUs — and follows reports that xAI has been renting compute to Cursor and has hired senior Cursor engineers. Cursor, founded in 2022, has seen rapid valuation growth (from $2.5 billion in early 2025 to a $29.3 billion post-money valuation in November) and has been reported to be pursuing a new round near $50 billion. The announcement comes as SpaceX prepares a blockbuster IPO (reports have cited a target valuation around $1.75 trillion and up to $75 billion raised) and has filed an S-1 disclosing that its more speculative plans — including space-based AI data centres and lunar/Mars industrialisation — rely on unproven technologies and may not be commercially viable.

UnitedHealth Group reported stronger-than-expected first-quarter 2026 results on April 21, posting adjusted EPS of $7.23 and revenue of $111.72 billion, topping Street estimates. Net income was roughly $6.3 billion and the company raised full-year adjusted earnings guidance to greater than $18.25 per share from a prior target above $17.75. Management said the medical loss ratio improved to 83.9% from 84.8 a year earlier, helped by repricing, reserve development and operational actions. UnitedHealthcare revenue rose to $86.3 billion with operating income of about $5.7 billion, while Optum Health delivered $1.3 billion of adjusted earnings and management reiterated a long-term Optum Health margin target of 6–8%. Executives outlined continued AI and digital investments (about $1.5 billion planned for 2026), leadership changes, exits from select non-U.S. businesses, and measures to streamline prior authorization and digital access. The company signalled a resumption of buybacks (roughly $2 billion planned this quarter). Shares jumped about 9–10% intraday. Management cautioned that medical utilization remains elevated and that regulatory and Medicare Advantage dynamics remain important risks to the recovery.

Northrop Grumman reported stronger-than-expected first-quarter 2026 results on April 21-22, with revenue of $9.88 billion (up about 4.4% year-on-year) and diluted EPS of $6.14, sharply higher than a year earlier. Aeronautics sales rose 17% to $3.28 billion, aided by B-21 program activity; Defense Systems organic sales climbed about 10% to roughly $1.9 billion. Net awards in the quarter totalled $9.8 billion and backlog stood near $96 billion. Management reaffirmed 2026 sales guidance of $43.5 billion to $44.0 billion and free cash flow guidance of $3.1 billion to $3.5 billion, while noting a first-quarter cash use of roughly $1.8 billion. The company has agreed with the U.S. Air Force to expand B-21 production capacity by 25% and accelerate the Sentinel ICBM replacement program; first B-21 delivery remains slated for 2027 and Sentinel first flight for 2027 with IOC in the early 2030s. Space Systems faced headwinds, including a $71 million GEM-63XL charge. Shares fell mid-single digits after the release; disclosures show ~$20.2 million of insider selling in recent months.

Tesla is heading into its Q1 2026 earnings season (reports April 21–22) under heightened investor scrutiny as the company balances slowing vehicle momentum with a strategic pivot to AI. Delivery tallies for the quarter came in at about 358,000 vehicles, below some forecasts, while Wall Street expects roughly $22.3 billion in revenue and EPS near $0.36; automotive gross margins are modeled near the mid-teens and free cash flow may be negative. Shares have fallen about 12–13% year-to-date and traded in the mid-$380s ahead of the report. Analysts are split — Wedbush reiterated an outperform with a $600 target, BofA remains bullish ($460) while Jefferies is more cautious (~$350). Separately, Samsung has sharply increased DRAM shipments to Tesla (reports say a three- to fourfold monthly rise) and plans to make advanced AI chips for Tesla at its Texas foundry in 2026, underscoring demand for in-car compute. Insider sales of roughly $20.9 million in the past three months, a very high P/E (mid-300s) and talk of rising 2026 capex (potentially >$20bn) add to near-term investor focus on margins, cash burn and updates on robotaxi/FSD and Optimus progress.